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Abstract
Introduction: Diabetic patients may develop acute lung injury less often than non-diabetics; a fact that could be
partially ascribed to the usage of antidiabetic drugs, including metformin. Metformin exhibits pleiotropic properties
which make it potentially beneficial against lung injury. We hypothesized that pretreatment with metformin
preserves alveolar capillary permeability and, thus, prevents ventilator-induced lung injury.
Methods: Twenty-four rabbits were randomly assigned to pretreatment with metformin (250 mg/Kg body weight/
day per os) or no medication for two days. Explanted lungs were perfused at constant flow rate (300 mL/min) and
ventilated with injurious (peak airway pressure 23 cmH2O, tidal volume ≈17 mL/Kg) or protective (peak airway
pressure 11 cmH2O, tidal volume ≈7 mL/Kg) settings for 1 hour. Alveolar capillary permeability was assessed by
ultrafiltration coefficient, total protein concentration in bronchoalveolar lavage fluid (BALF) and angiotensin-
converting enzyme (ACE) activity in BALF.
Results: High-pressure ventilation of the ex-vivo lung preparation resulted in increased microvascular permeability,
edema formation and microhemorrhage compared to protective ventilation. Compared to no medication,
pretreatment with metformin was associated with a 2.9-fold reduction in ultrafiltration coefficient, a 2.5-fold
reduction in pulmonary edema formation, lower protein concentration in BALF, lower ACE activity in BALF, and
fewer histological lesions upon challenge of the lung preparation with injurious ventilation. In contrast, no
differences regarding pulmonary artery pressure and BALF total cell number were noted. Administration of
metformin did not impact on outcomes of lungs subjected to protective ventilation.
Conclusions: Pretreatment with metformin preserves alveolar capillary permeability and, thus, decreases the
severity of ventilator-induced lung injury in this model.
Introduction
Despite its firmly established role as a fundamental life-
support modality for critically ill patients, mechanical ven-
tilation (MV) may elicit ventilator-induced lung injury
(VILI), which is characterized by alveolar edema and
hemorrhage. Recognized mechanisms of VILI include
alveolar over-distention by high tidal volumes (volu-
trauma) and cyclic opening and closing of alveoli (atelec-
trauma), which operate in concert to trigger inflammatory
processes (biotrauma), oxidant/antioxidant imbalance,
intra-alveolar coagulation and disturbances in surfactant
function [1,2].
Clarification of the above pathophysiologic mechanisms
serves a basis for the discovery of effective pharmacologi-
cal therapies against VILI, which currently is mainly pre-
vented through the limitation of the mechanical insult to
the lung parenchyma (that is, through the implementation
of protective ventilation) [3]. Such pharmacological thera-
pies could be novel agents, for example, sphingosine
1-phosphate [4], or drugs already in clinical use. Our
research group contributed to the idea that established
drugs may indeed be beneficial when they are re-used for
indications other than their initial indication, a concept
which we call the drug recycle concept; indeed, we
reported that pretreatment with atorvastatin attenuates
VILI [5]. Reduced cost, clinician familiarity and known
undesired effects profile are obvious advantages of using
drugs with proven efficacy for a different indication.
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Such a popular established drug is metformin (N’,N’-
dimethylbiguanide), which enjoys a long-standing recogni-
tion in the setting of type 2 diabetes mellitus. Metformin
recently emerged as a potential adjunct in the manage-
ment of patients with cancer [6-8]; a fact indicating that it
may also have effects other than its antihyperglycemic
ones. Indeed, there is growing (albeit still limited) evidence
that metformin might exhibit pleiotropic properties,
including anti-angiogenic [9], anti-inflammatory [10], anti-
oxidant [11] and endothelial barrier-enhancing [12]. Some
of the above properties might make metformin a potential
candidate for protection against VILI as well.
Interestingly, several clinical studies point out that dia-
betic patients develop acute lung injury (ALI)/acute
respiratory distress syndrome (ARDS) less frequently than
non-diabetics [13-15]; a benefit that could be partially
ascribed to the usage of antidiabetic therapies, such as
metformin [16]. This evidence (derived from observational
studies) [13-15] along with the known pleiotropic effects
of metformin (derived from experimental studies) [9-12]
generated the research idea that it could indeed prevent
lung injury. Thus, we endeavored to test the hypothesis
that pretreatment with metformin preserves pulmonary
vascular permeability, and therefore, confers protection
against VILI in non-diabetic animals.
Materials and methods
Animal care and pretreatment
A previously described isolated rabbit lung model was
implemented [5]. Male New Zealand white rabbits
(approximately 3 kg) were used for these experiments,
which were conducted in accordance with the 160/1991
Council Directive of European Union. All experimentation
was approved by the Institutional Review Board of the
Attikon Hospital and by the Veterinary Directorate of the
Prefecture of Athens.
Experiment animals were given metformin (250 mg/kg
body weight/day per os in drinking water) or no medica-
tion, 48 hours and 24 hours before surgery.
Surgical dissection
Detailed information is available in Additional file 1.
Description of the circuit
Perfusate
The perfusate consisted of 350 mL of Krebs-Henseleit
solution (to which 5% bovine serum albumin was added)
plus 40 mL of autologous blood (serving as a marker for
capillary rupture) to achieve a total volume of 390 mL.
Circuit
The perfusion circuit consisted sequentially of the left
atrium cannula, a venous plastic tubing with its free distal
end open to atmosphere, the venous reservoir collecting
the perfusate from the venous plastic tubing, a digital
rotary pump and an arterial plastic tubing leading conse-
quently to a water bath, a bubble trap and finally to the
pulmonary artery cannula and the lungs.
Initial hemodynamic and ventilation settings
As previously described [5], each heart-lung preparation
was connected to a ventilator and the lungs were initially
recruited with continuous positive airway pressure (CPAP)
of 20 cmH2O. Then, each preparation was ventilated with
pressure-control ventilation (PCV) at peak inspiratory
pressure of 11 cmH2O, positive end-expiratory pressure
(PEEP) of 3 cmH2O, respiratory rate of 15 breaths/minute,
inspiration:expiration ratio of 0.5 and fraction of inspired
oxygen of 0.21, while the blood flow increased gradually to
300 mL/minute. Heart-lung preparations were maintained
in these conditions (that is, constant perfusion with
300 mL/minute and mechanical ventilation with PCV
11:3) for the next 16 minutes and were subsequently
switched to CPAP 5 cmH2O to measure the ultrafiltration
coefficient (Kf,c) [17,18].
Group allocation and ventilation/perfusion protocol
After measurement of the baseline Kf,c, each lung prepara-
tion was randomly allocated to be ventilated with PCV at
peak inspiratory pressures of 23 cmH2O (high pressure,
HiP) or 11 cmH2O (low pressure, LoP) for 60 minutes.
Four experimental groups of lung preparations were set:
high pressure metformin pretreatment (HiP-Met); high
pressure no metformin (HiP-C); low pressure metformin
pretreatment (LoP-Met) and low pressure no metformin
(LoP-C). Experiments were not performed in a blinded
manner.
Post-ventilation protocol measurements
After the completion of the ventilation protocol and the
measurement of the final Kf,c, the blood flow and ventila-
tion were stopped. The following variables were consid-
ered as outcomes for our study:
ΔKf,c (that is, final Kf,c - baseline Kf,c) was the change
in Kf,c before and after the institution of the 60-minute
ventilation protocol. ΔKf,c indicated pulmonary capillary
permeability alterations. Weight gain was the weight of
the heart-lung preparation at 20, 40 and 60 minutes
minus its weight after 1 minute of the ventilation proto-
col. Given that the weight of the heart could not change
during the ventilation, this variable reflected the change
in lung weight and, eventually, it served as a surrogate for
formation of pulmonary edema. Changes in pulmonary
artery pressure (mean, inspiratory and expiratory) were
defined as the pulmonary arterial pressure at 20, 40 and
60 minutes minus the pulmonary arterial pressure after
1 minute of the ventilation protocol. Changes in tidal
volume were defined as the tidal volume at 20, 40 and
60 minutes minus the tidal volume after 1 minute of the
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ventilation protocol. Total protein concentration in
bronchoalveolar lavage fluid (BALF) was measured, as
previously described [5].
Angiotensin-converting enzyme (ACE) activity in BALF
was measured following incubation of BALF with ACE
substrate hippuryl-histidine-leucine and using a previously
described fluorometric assay [19]. Increased levels of ACE
activity in BALF indicated diffusion of this enzyme into
the alveolar spaces and, thus, served as a marker of pul-
monary microvascular barrier disruption [19].
The total cell number in BALF was calculated using a
hemocytometer.
Histology
The left lung was fixed for histology and a composite
histological score was determined as previously
described [5,20,21].
Statistical analysis
GraphPad Prism 5 (La Jolla, CA, USA) was used for statis-
tical analyses. Data were summarized as means ± standard
deviation. One way analysis of variance was used to deter-
mine the statistical significance of between-group differ-
ences. Statistically significant results (P < 0.05) were
further examined by post hoc analysis using the Student
Newman-Keuls test. For outcomes such as BALF protein,
BALF ACE activity, BALF total cell number and histology,
where data from four animals per group were available,
data were summarized as medians (range) and compared
using the non-parametric Kruskal-Wallis test.
Results
Of the thirty-two animals sacrificed for this experiment,
eight animals were omitted before the measurement of the
baseline Kf,c according to prespecified exclusion criteria.
Thus, lung preparations from twenty-four rabbits (specifi-
cally, seven animals per HiP group and five animals per
LoP group) were used.
No difference was found between the compared groups
in serum glucose level at baseline (Table 1). HiP groups
(that is, HiP-Met versus HiP-C) did not differ in terms of
baseline characteristics (Table 1). At the beginning of the
mechanical ventilation, HiP groups exhibited higher tidal
volume than LoP groups (HiP 16.5 ± 1.9 mL/kg vs. LoP
6.8 ± 1.5 mL/kg). With respect to the values of perfusate
pH, arterial oxygen tension (PaO2) and arterial carbon
dioxide tension (PaCO2), HiP-Met and HiP-C groups did
not differ at any time of ventilation (data provided in
Additional file 1).
Pulmonary capillary permeability (Kf,c)
At baseline, compared groups did not differ with regard
to Kf,c (expressed in g/min/mmHg/100 g) (Table 1). At
the end of ventilation, final Kf,c was greater in the HiP-C
group than in both the LoP-C and LoP-Met groups, but
there was no difference between the HiP-Met and either
of the LoP groups (Figure 1).
Among lungs ventilated at the higher peak inspiratory
pressure/higher tidal volume, pretreatment with metfor-
min compared to no pretreatment was associated with
lower final Kf,c (HiP-Met 0.267 ± 0.205 vs. HiP-C 0.881
Table 1 Characteristics of the compared groups at baseline.
Variables LoP-C LoP-Met HiP-C HiP-Met
Animal weight, kg 3.2 ± 0.2 3.4 ± 0.2 3.3 ± 0.4 3.0 ± 0.3
Serum glucose, mg/dL 179 ± 44 182 ± 91 152 ± 93 144 ± 59
Initial lung weight, g 24.1 ± 2.4 24.4 ± 2.3 23.8 ± 2.5 20.6 ± 2.7
Ischemic time, minutes 34.6 ± 5.5 39.0 ± 7.1 39.0 ± 6.8 34.4 ± 4.9
Before the beginning of 60-minute ventilation
PPAmean, mmHg 20.4 ± 3.5 24.8 ± 7.5* 16.8 ± 3.1* 16.7 ± 4.0*
PPAinspir, mmHg 24.9 ± 3.8 30.8 ± 8.4 22.5 ± 4.4 22.0 ± 4.4
PPAexpir, mmHg 18.4 ± 3.7 21.4 ± 6.7* 13.9 ± 2.7* 12.9 ± 2.2*
Pcap, mmHg 7.5 ± 1.8 7.0 ± 0.6 6.3 ± 0.4 6.8 ± 0.6
Kf,c, g/min/mmHg/100g 0.185±0.09 0.147±0.05 0.209±0.07 0.244±0.11
At the beginning of 60-minute ventilation:
pH 7.33 ± 0.17 7.27 ± 0.09 7.32 ± 0.11 7.33 ± 0.07
PaO2, mmHg 161 ± 9** 154 ± 9 147 ± 2** 147 ± 8
PaCO2, mmHg 44.7 ± 19.9 47.2 ± 6.6 44.8 ± 5.4 44.7 ± 7.3
T, °C 35.9 ± 0.5 35.2 ± 0.8 36.2 ± 0.8 35.6 ± 0.5
LoP-C: low pressure-no metformin; LoP-Met: low pressure-metformin; HiP-C: high pressure-no metformin; HiP-Met: high pressure-metformin; PPAmean: mean
pulmonary arterial pressure; PPAinspir: inspiratory pulmonary arterial pressure; PPAexpir: expiratory pulmonary arterial pressure; Pcap: pulmonary capillary
hydrostatic pressure; Kf,c: ultrafiltration coefficient; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; T: temperature. Results are presented as
means ± standard deviation; n = 7 animals per HiP group and 5 animals per LoP group. *P < 0.01 for comparison between the LoP-Met and both HiP groups; **P
< 0.05 for comparison between the LoP-C and HiP-C group.
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± 0.605) (Figure 1) and lower ΔΚf,c (HiP-Met 0.023 ±
0.266 vs. HiP-C 0.672 ± 0.613).
Pulmonary edema formation (weight gain)
The HiP-C group developed more edema than both LoP
groups at 20, 40 and 60 minutes of ventilation (Figure
2), but the HiP-Met group did not differ from either
LoP group (Figure 2).
Among lungs ventilated at the higher peak inspiratory
pressure/higher tidal volume, those with, as opposed to
those without metformin pretreatment, sustained less
weight gain at 20 minutes (HiP-Met 1.01 ± 0.47 g vs.
HiP-C 3.32 ± 3.02 g), 40 minutes (HiP-Met 1.76 ± 1.18
g vs. HiP-C 5.96 ± 4.01 g) and 60 minutes (HiP-Met
2.91 ± 2.38 g vs. HiP-C 7.35 ± 4.32 g) of mechanical
ventilation (Figure 2). This was also the case after
adjustment of weight gain for initial lung weight.
Changes in pulmonary arterial pressure
There was no difference between the compared groups
in increase in mean pulmonary arterial pressure at any
time of ventilation. This was also the case for the
expiratory and the inspiratory pulmonary pressure.
Changes in tidal volume
As shown (Figure 3), there was a greater increase in
tidal volume in the HiP groups than in the LoP groups
at all ventilation times. In contrast, there was no differ-
ence between the HiP-Met and HiP-C groups.
Gross examination of the lungs
After the end of injurious ventilation, we noticed more
edema and more hemorrhagic spots on the surface of
the lungs exposed in injurious (HiP) compared to pro-
tective (LoP) ventilation. Among the HiP groups, on
gross observation there was less edema and fewer
hemorrhagic spots on the lungs of animals with metfor-























Figure 1 Ultrafiltration coefficient measured at baseline
(baseline Kf,c) and after the ventilation protocol (final Kf,c).
Results are presented as means ± standard deviation; n = 7 animals
per HiP group and 5 animals per LoP group. *P < 0.05 for HiP-C
group vs. all other groups. LoP-C: low pressure-no metformin; LoP-

























Figure 2 Weight gain at different time points during the
ventilation protocol. Results are presented as means ± standard
deviation; n = 7, 6 and 5 animals for HiP-C, HiP-Met and LoP
groups, respectively. *P < 0.05 for HiP-C group vs. all other groups;
** P < 0.01 for HiP-C group vs. all other groups; *** P < 0.05 for HiP-
C group vs. HiP-Met and P < 0.001 for HiP-C group vs. LoP groups.
LoP-C: low pressure-no metformin; LoP-Met: low pressure-
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Figure 3 Changes in tidal volume at different time points
during the ventilation protocol. Results are presented as means ±
standard deviation. n = 7, 6 and 5 animals for HiP-C, HiP-Met and
LoP groups, respectively. *P < 0.05 for HiP groups vs. LoP groups.
LoP-C: low pressure-no metformin; LoP-Met: low pressure-
metformin; HiP-C: high pressure-no metformin; HiP-Met: high
pressure-metformin.
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Protein concentration in BALF
Among the HiP groups, those with metformin pre-
treatment had lower total protein concentration in
BALF compared to those without (HiP-Met 0.57, range
0.49 to 1.05 mg/mL vs. HiP-C 1.75, range 0.99 to 2.53
mg/mL) after the end of 60 minutes of ventilation
(Figure 4).
ACE activity in BALF
After the end of injurious ventilation, animals pretreated
with metformin (HiP-Met) presented lower levels of
ACE activity in BALF compared to untreated animals
(HiP-C) (Figure 5).
Total cell number in BALF
There was no difference between the compared groups
in the total cell number in BALF.
Histology
In lungs ventilated at the higher peak inspiratory pres-
sure/higher tidal volume, metformin pretreatment, as
opposed to no pretreatment, was associated with fewer
histological lesions in terms of perivascular hemor-
rhage (HiP-Met 0, range 0 to 0) vs. HiP-C 2, range
0 to 2) and composite histological score (HiP-Met
1.25, range 1.0 to 1.5) vs. HiP-C 3.5, range 3.0 to 5.0)
(Figure 6). In contrast, no difference was demonstrated
between the HiP-Met and HiP-C groups in capillary
congestion and infiltration of alveolar spaces by neu-
trophils. We did not observe intra-alveolar hemor-
rhage, interstitial infiltration, hyaline membrane
formation or thickening of the basal membrane in any
of the groups.
Discussion
The findings of the present study suggest that pretreat-
ment with metformin prevented increases in pulmonary
microvascular permeability in response to injurious
mechanical ventilation, thus attenuating VILI in terms
of edema formation and histology.
One may wonder if this beneficial effect of metformin
against VILI could be attributed to the modification of
the serum glucose level of treated animals rather than
the metformin itself. The evidence (albeit controversial)
that hyperglycemia promotes ALI might justify this
notion [13,22]. However, serum glucose levels did not
differ in the groups compared in our study. This was
congruent with the results of other experiments that
also showed that administration of metformin in non-
diabetic animals did not alter their glycemic status [10].
Similarly, administration of metformin does not influ-
ence serum glucose in humans who are not suffering
from diabetes mellitus [23]. Thus, metformin appears to
prevent VILI by a mechanism other than its antihyper-
glycemic action.
By measuring the pulmonary microvascular filtration
coefficient Kf,c, an accurate marker of pulmonary micro-
vascular permeability [24,25], in addition to BALF protein
and ACE activity levels, we observed that metformin pre-
vented the rise in endothelial permeability upon challenge
of the isolated lung preparation with excessive airway
pressure, indicating a direct barrier-stabilizing effect of the
drug. In line with our results, other investigators have
advocated that metformin restores pulmonary endothelial
function after injurious stimuli other than over-distention,
such as hypoxia, through activation of adenosine mono-
phosphate-activated protein kinase [12]. Interestingly, ben-
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Figure 4 Total protein concentration in bronchoalveolar lavage
fluid (BALF). Results are presented as medians (range); n = 4
animals per group. *P < 0.05 for HiP-C group vs. other groups. LoP-
C: low pressure-no metformin; LoP-Met: low pressure-metformin;
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Figure 5 Angiotensin-converting enzyme (ACE) activity in
bronchoalveolar lavage fluid (BALF). Results are presented as
medians (range); n = 4 animals per group. *P < 0.05 for HiP-C
group vs. HiP-Met and LoP-C groups. LoP-C: low pressure-no
metformin; LoP-Met: low pressure-metformin; HiP-C: high pressure-
no metformin; HiP-Met: high pressure-metformin; FU: fluorescence
units.
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organs other than lung were repeatedly reported [26,27],
indicating that metformin might act similarly on the pul-
monary vascular endothelium as well, hence justifying
further research in the field.
Agard and colleagues reported that metformin exhibits
vasodilatory effects and therefore, it protects against
experimental pulmonary hypertension [12]. This finding
[12], in conjunction with evidence regarding the impact
of pulmonary hypertension (combined with high airway
pressure) on the development of lung injury [28], could
lead to the claim that mitigation of VILI in our study
could take place through improvements in hemody-
namics. However, we found no difference between the
metformin (HiP-Met) and the no metformin (HiP-C)
groups in pulmonary arterial pressure at any time of
injurious ventilation, and given the constant-flow
conditions and pulmonary venous pressure of our sys-
tem, no differences in pulmonary vascular resistance can
be expected between the groups. Thus, the putative vaso-
dilatory effects of metformin (as indicated by the deter-
mination of pulmonary arterial pressure in the HiP
groups) appear not to contribute to the attenuation of
lung injury under the present experimental conditions.
Likewise, other pleiotropic effects of metformin, such
as anti-inflammatory effects [10], may also not participate
in its benefit against VILI in the present study. Our
experimental protocol had a negligible amount of leuco-
cytes in the perfusate and a short duration of injurious
ventilation, so there was not enough time for inflamma-
tory pathways to be activated. Indeed, we found no differ-
ence between the compared groups in terms of the BALF
total cell number and infiltration of alveolar spaces by
Figure 6 Histological lesions due to mechanical ventilation. Representative histological sections show less perivascular hemorrhage in
metformin-pretreated (HiP-Met) compared to untreated (HiP-C) animals after exposure to one hour of injurious ventilation. Perivascular
hemorrhage was not observed in the lungs of animals exposed to protective ventilation (LoP-C). Results are presented as medians (range); n = 4
animals per group. *P < 0.05 for HiP-C group vs. all other groups. LoP-C: low pressure-no metformin; LoP-Met: low pressure-metformin; HiP-C:
high pressure-no metformin; HiP-Met: high pressure-metformin.
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neutrophils. Thus, in our model of VILI (in which
mechanical phenomena rather than inflammation are the
major determinants of injury), it seems unlikely that a
drug could provide benefit by acting as an anti-inflamma-
tory agent.
A comment on our results of the changes in tidal
volume during the 60-minute ventilation period may be
worthwhile (Figure 3). Indeed, we observed an increase in
the tidal volume in lungs ventilated at the higher peak
inspiratory pressure/higher tidal volume (HiP groups) dur-
ing the early phases of injurious ventilation, which (given
the applied PCV mode of ventilation) could be translated
into an increase in compliance (Figure 3). This increase in
compliance after the initiation of high pressure ventilation
is a consistent finding in our ex-vivo experiments
[5,20,21]. On the other hand, as depicted in Figure 3, dur-
ing the last 20 minutes of the injurious ventilation, lungs
in the HiP-C, but not the HiP-Met group, sustained a
decrease in tidal volume (and thus, in compliance). This
could be explained by the formation of pulmonary lung
edema in the HiP-C group as VILI proceeded.
Careful combing of the literature may reveal several
(indirect) indications that usage of metformin might pre-
vent ALI. Specifically, during the last few years, there is
accumulating clinical evidence that a medical history of
diabetes mellitus predicts reduced susceptibility to ALI/
ARDS in patients at risk. Indeed, at least three large
cohorts of patients with risk factors for ALI/ARDS
(namely sepsis/septic shock, trauma and massive transfu-
sion) inferred that there is a protective association
between diabetes and ALI/ARDS, even after adjustment
for potential confounders [13-15]. In a relevant review, it
was assumed that diabetes may merely be a confounder
and instead other factors related to the management of
diabetic patients, such as antihyperglycemic therapies,
may account for the observed protection of such patients
[16]; the lack of firm evidence that acute hyperglycemia
(a cardinal feature of diabetes) alone modulates ALI
makes this assumption reasonable [13,29]. Metformin is
a very commonly prescribed anti-diabetic medication;
thus, it may mediate the relative protection of diabetic
patients against the development of ALI.
Our isolated lung model, albeit well-established for the
research of VILI, entails unavoidable limitations. First, it is
an ex-vivo model, which means that lungs do not interact
with other organs or the lymphatic or the nervous system.
However, this model provides us with the ability to accu-
rately measure the Kf,c and, thereby, to reliably assess the
improvements in alveolar capillary permeability achieved
by the administration of metformin [24,25]. In addition, it
allows us to continuously monitor the formation of
edema, and pulmonary arterial pressure over time.
Second, although our ex-vivo rabbit lung model pro-
vided us with the ability to make an intriguing observation
(namely, metformin preserves alveolar capillary permeabil-
ity despite injurious ventilation), it could not allow us to
gain a mechanistic insight into how metformin affords this
benefit. For example, we were unable to examine whether
metformin protects through inhibition of the mitochon-
drial function and oxidative burst of leukocytes [30].
There is evidence that metformin induces a hypometabolic
state [31], which in turn might be beneficial against injury
[32]. Additional in-vivo animal studies are justified, focus-
ing on the mechanism through which metformin prevents
VILI.
Third, our choice to administer a dose of metformin as
high as 250 mg/kg/day and not to check for actual drug
intake might be questioned. Rare reports that metformin
is associated with lactic acidosis, which is surprisingly of
good prognosis [33], might justify this criticism. How-
ever, the risk for lactic acidosis due to metformin seems
to be overestimated according to a recent relevant meta-
analysis [34]. Given that we did not measure pH and
lactate concentration in the blood of rabbits before sacri-
ficing them, we could not preclude subclinical lactic
acidosis. However, we did not observe any apparent
adverse event after administration of the drug. Similarly,
several other investigators who gave the same dosage of
metformin (250 mg/kg) did not notice any toxicity
[10,35].
Fourth, data on several outcomes (namely BALF protein,
BALF ACE activity, BALF total cell number and histology)
were derived from only four animals per group. In an
attempt to address this concern, we treated these data
conservatively; specifically, we summarized them as the
median and the range and compared these using non-
parametric tests. Finally, we noticed that our HiP-C group
sustained less injury than in our previous study [5]. How-
ever, given that all groups (HiP-Met, HiP-C, LoP-Met and
LoP-C) in the present study were compared during the
same time period and under the same experimental condi-
tions (that is, without the use of historical controls), this
could not affect the robustness of our results.
Conclusions
The findings of the present study demonstrate that pre-
treatment with the widely used antidiabetic agent met-
formin protects against VILI under the present
experimental conditions. These results expand our
knowledge regarding the non-antidiabetic effects of met-
formin and may be of clinical value. Should these results
be replicated in an in-vivo animal model of VILI, they
might provide a rationale for carrying out observational
studies that will examine the relationship between
administration of metformin and development of ALI/
ARDS. The fact that metformin is inexpensive and
already widely used may make execution of such trials
feasible.
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Key messages
• Oral administration of metformin does not cause
hypoglycemia or other apparent adverse events in
non-diabetic rabbits.
• Administration of metformin decreases the severity
of VILI.
Additional material
Additional file 1: Detailed methods, and table giving detailed
information regarding animal care and pretreatment, surgical
dissection, description of the circuit, measurement of baseline
ultrafiltration coefficient, exclusion criteria, group allocation and
ventilation/perfusion protocol, post-ventilation protocol
measurements and histology. Characteristics (pH, arterial oxygen
tension and arterial carbon dioxide tension) of the compared groups at
different time points during the 60-minute ventilation period are
depicted.
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ACE: angiotensin-converting enzyme; ALI: acute lung injury; ARDS: acute
respiratory distress syndrome; BALF: bronchoalveolar lavage fluid; CPAP:
continuous positive airway pressure; ΔKf,c: change in ultrafiltration
coefficient; HiP: high pressure; HiP-C: high pressure-no metformin; HiP-Met:
high pressure-metformin pretreatment; Kf,c: ultrafiltration coefficient; LoP:
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metformin pretreatment; MV: mechanical ventilation; PaCO2: arterial carbon
dioxide tension; PaO2: arterial oxygen tension; PCV: pressure-control
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lung injury.
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